EUCTR2007-001670-84-SE进行中（未招募）不适用
Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure - ASCEND-HF
Jassen-Cilag International NV,Turnhoutseweg 30, 2340 Beerse, Belgium0 个研究点目标入组 7,000 人开始时间: 2007年8月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 7,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Men or women 18 years of age or older
- •-Hospitalized for the management of ADHF or diagnosed with ADHF within 48 hours after being hospitalized for another reason
- •The diagnosis of ADHF must meet the following definition:
- •–Dyspnea at rest or dyspnea with minimal activity (i.e., difficulty breathing at rest while sitting, or difficulty breathing while lying flat or with 1 pillow, or difficulty breathing with minimal activity such as talking, eating),
- •–At least 1 of the following signs:
- •–Tachypnea with respiratory rate >20 breaths per minute, OR
- •–Pulmonary congestion/edema with rales or crackles/crepitations at least one-third above lung base,
- •–At least 1 of the following objective measures:
- •–Chest x-ray with pulmonary congestion/edema, OR
- •–B-type natriuretic peptide =400 pg/mL or NT-proBNP =1,000 pg/mL at presentation, OR
- •–Pulmonary capillary wedge pressure >20 mmHg, OR
- •–Ejection fraction <40% measured by any modality (echocardiography, nuclear testing, cardiac MRI, ventricular angiography) within 12 months before randomization without intervening revascularization or cardiac surgery
- •-Signed (by the subjects or their legally acceptable representatives) informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
- •-Signed (by the subjects or their legally acceptable representatives) informed consent form for pharmacogenomic research indicating consent or refusal to participate in the pharmacogenomic component of the study (where local regulations permit). Participation in this component is not required for participation in the clinical study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Hospitalized for =48 hours before randomization
- •- Likely to be discharged from the hospital in 24 hours or less
- •At high risk for hypotension:
- •-Baseline SBP <100 mmHg or
- •-Systolic blood pressure <110 mmHg with i.v. nitroglycerin or another i.v. vasodilator used at baseline
- •- Persistent, uncontrolled hypertension (SBP >180 mmHg)
- •Have any of the following cardiovascular disease parameters:
- •Electrocardiogram (ECG) with new ST elevation >1 mm in 2 consecutive leads
- •Acute coronary syndrome as primary diagnosis
- •A coronary catheterization or other coronary intervention is planned within 48 hours
- •History of cardiac valvular stenosis, restrictive cardiomyopathy, hypertrophic obstructive cardiomyopathy, or pericardial tamponade
- •Cardiac index >2.5 l/min/m2 or PCWP =20 mmHg, or both, within 6 hours before randomization (only if measured)
- •Have a left ventricular assist device
- •Medication History:
- •Received first i.v. treatment of diuretics, vasodilators or inotropes for HF more than 24 hours before randomization
- •Treated with levosimendan or milrinone within 30 days before randomization or anticipated need for one of these medications during the current hospitalization
- •Treated with i.v. nitroglycerin, i.v. dobutamine <5 mg/kg/min or another i.v. vasoactive medication, the dosage of which is not stable for 3 hours before randomization
- •Treated with dobutamine greater than or equal to 5 mg/kg/min. at the time of randomization
- •Had prior therapy with nesiritide in the past 30 days, or anticipate the need for open-label nesiritide during the current hospitalization
- •Known allergic reaction or hypersensitivity to nesiritide
- •- Laboratory abnormalities (when laboratory values are available)
- •Troponin level >5 times the upper limit of normal (ULN)
- •Creatine kinase - MB (CK-MB) levels >3 times ULN
- •BNP or NT-proBNP is within normal limits (i.e., BNP <100 pg/mL or NT-proBNP <125 pg/mL for subjects <75 years old; NT proBNP <425 pg/mL for subjects greater than or equal to 75 years old)
- •- Comorbid Diseases
- •Chronic or intermittent renal support therapy (hemodialysis, ultrafiltration, or peritoneal dialysis)
- •Significant chronic or acute lung disease that might interfere with the ability to interpret the dyspnea assessments (e.g., severe chronic obstructive pulmonary disease, active asthma or acute pneumonia)
- •Serious comorbid disease in which the life expectancy of the subject is less than 6 months – e.g., acute systemic infection – sepsis, metastatic cancer or other serious illnesses
- •Anemia, defined as hemoglobin <9 g/dL (<5.6 mmol/L) or hematocrit <27%
- •Active gastrointestinal bleeding
- •- Received an experimental drug or used an experimental medical device within 30 days before randomization
- •- Previous enrollment in a nesiritide study
- •- Pregnant, suspected to be pregnant, or breast-feeding
- •- Unwillingness or inability to comply with study requirements (including subjects whose cooperation is doubtful due to drug abuse or alcohol dependency)
研究者
相似试验
进行中（未招募）
不适用
Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure - ASCEND-HFAcute Decompensated Heart FailureEUCTR2007-001670-84-NLJanssen-Cilag International NV,Turnhoutseweg 30, 2340 Beerse, Belgium7,000
进行中（未招募）
不适用
Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure - ASCEND-HFDecompensated Hearth FailureMedDRA version: 9.1Level: LLTClassification code 10061216Term: InfarctionEUCTR2007-001670-84-ITJANSSEN-CILAG INTERNATIONAL NV7,000
已完成
3 期
Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart FailureNL-OMON31659Janssen-Cilag75
进行中（未招募）
不适用
Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure - ASCEND-HFMedDRA version: 9.1Level: LLTClassification code 10064653Term: Acute decompensated heart failureAcute Decompensated Heart FailureEUCTR2007-001670-84-BGJassen-Cilag International NV,Turnhoutseweg 30, 2340 Beerse, Belgium7,000
进行中（未招募）
不适用
Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure - ASCEND-HFMedDRA version: 9.1Level: LLTClassification code 10064653Term: Acute decompensated heart failureAcute Decompensated Heart FailureEUCTR2007-001670-84-LTJassen-Cilag International NV,Turnhoutseweg 30, 2340 Beerse, Belgium7,000